RxDoctor Payments Data

Marisa Gentry, NP

Primary Care · Columbia, SCNPI 1518374586

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,190, 7.4 times the $161 reported in 2022.

$2,057in general payments, 2019–2025

Across 113 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$288
  • AbbVie$223
  • Novo Nordisk$211
  • AstraZeneca$197
  • Pfizer$137
  • Exact Sciences$126
  • plus $875 from 22 others

What the payments were for

  • Food & beverage$1,98797%
  • Education$703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,057 in reported general payments places this provider in the 75th percentile of 115 primary care providers in South Carolina.

See all primary care providers in South Carolina

Medicare billing

Part B allowed, 2024
$64,129
Medicare patients
135
Services billed
1,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$130,574
FarxigaDapagliflozin Propanediol72$72,529
JardianceEmpagliflozin28$32,461
RybelsusSemaglutide16$31,437
MyrbetriqMirabegron19$14,608
Breo ElliptaFluticasone/Vilanterol11$6,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,065
Ezetimibe38$2,946
Esomeprazole Magnesium32$2,065
Rosuvastatin Calcium182$2,028
Levothyroxine Sodium156$1,644
Losartan Potassium94$1,379
Duloxetine Hcl41$1,364
Atorvastatin Calcium148$1,327
Albuterol Sulfate HfaAlbuterol Sulfate45$1,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$211$162,010111 claims
AstraZenecaFarxiga$197$72,52972 claims
Boehringer IngelheimJardiance$63$32,46128 claims
Astellas Pharma US IncMyrbetriq$123$14,60819 claims
GSKBreo Ellipta$17$6,03111 claims
AbbVieSynthroid$223$92317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 115 primary care providers in South Carolina.

Other primary care in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →